Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Deferred Taxes (2024 - 2025)

Adma Biologics' Deferred Taxes history spans 2 years, with the latest figure at -$20.9 million for Q4 2025.

  • For Q4 2025, Deferred Taxes fell 124.76% year-over-year to -$20.9 million; the TTM value through Dec 2025 reached -$11.0 million, down 113.08%, while the annual FY2025 figure was -$11.0 million, 113.08% down from the prior year.
  • Deferred Taxes reached -$20.9 million in Q4 2025 per ADMA's latest filing, down from $4.8 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $84.3 million in Q4 2024 to a low of -$20.9 million in Q4 2025.